Clinical Trials, Phase III as Topic
-
Subject Areas on Research
-
A Bayesian perspective on Biogen's aducanumab trial.
-
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
-
A combined clinical and biomarker approach to predict diuretic response in acute heart failure.
-
A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery.
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
-
A hub for bench-to-bedside pharmacogenomic-based research.
-
A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.
-
A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
-
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
-
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
-
Achieving the goals of effective, safe, and individualized cancer care.
-
Acute ischemic heart disease.
-
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
-
Adaptive design methods in clinical trials - a review.
-
Adjusting for misclassification in a stratified biomarker clinical trial.
-
Adjuvant therapy for pancreatic cancer: current status and future directions.
-
Adjuvanted Immunotherapy Approaches for Peanut Allergy.
-
Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials.
-
Analysis of site performance in academic-based and community-based centers in the IDEAL Study.
-
Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis.
-
Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
-
Antiretroviral therapy: evaluating the new era in HIV treatment.
-
Antivirals for adult patients hospitalized with SARS-CoV-2 infection: A randomized, Phase II/III, multicenter, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX - REVOLUTIOn: protocol and statistical analysis plan.
-
Aptamers: an emerging class of therapeutics.
-
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
-
Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
-
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
-
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
-
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis.
-
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
-
Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
-
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
-
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
-
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
-
Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.
-
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
-
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?
-
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
-
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
-
COVID-19 Vaccination and Obesity: Optimism and Challenges.
-
Cabozantinib in genitourinary malignancies.
-
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
-
Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award.
-
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.
-
Ceftaroline: a cephalosporin with expanded Gram-positive activity.
-
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
-
Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.
-
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.
-
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
-
Comments on concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a mist of mysterious results.
-
Community consultation for prehospital research: experiences of study coordinators and principal investigators.
-
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
-
Comparative Effectiveness of Tumor Response Assessment Methods: Standard of Care Versus Computer-Assisted Response Evaluation.
-
Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
-
Comparison of futility monitoring guidelines using completed phase III oncology trials.
-
Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.
-
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
-
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
-
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
-
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
-
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.
-
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
-
Cost-Effectiveness Analysis of Qsymia for Weight Loss.
-
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
-
Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.
-
Design and Analysis of Biosimilar Switching Studies.
-
Design issues in randomized phase II/III trials.
-
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.
-
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
-
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
-
Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
-
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.
-
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
-
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
-
Early complement genes are associated with visual system degeneration in multiple sclerosis.
-
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
-
Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
-
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
-
Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
-
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
-
Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
-
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors.
-
Eptifibatide in percutaneous coronary intervention. A review.
-
Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.
-
European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.
-
Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
-
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
-
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy.
-
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
-
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
-
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
-
Frailty models with missing covariates.
-
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
-
Glioblastoma multiforme: a review of where we have been and where we are going.
-
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.
-
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
-
HPV vaccines: now that they're here, how do we maximize their benefit?
-
Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles.
-
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.
-
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
-
Hyperthermic treatment of malignant diseases: current status and a view toward the future.
-
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
-
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
-
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.
-
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
-
Immune correlates of protection for dengue: State of the art and research agenda.
-
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
-
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
-
Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
-
Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
-
Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001.
-
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
-
Intersociety Council on Radiation Oncology essay on the introduction of new medical treatments into practice.
-
Lessons learned from clinical trials in acute heart failure: phase 3 drug trials.
-
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
-
Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
-
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial.
-
Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition).
-
Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
-
Mechanisms and Models in Heart Failure: A Translational Approach.
-
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
-
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
-
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.
-
Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.
-
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
-
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
-
Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
-
New applications of disease genetics and pharmacogenetics to drug development.
-
New treatment options in castration-resistant prostate cancer.
-
Noncollagen Dermal Fillers: A Summary of the Clinical Trials Used for Their FDA Approval.
-
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).
-
On model specification and selection of the Cox proportional hazards model.
-
On the design and the analysis of stratified biomarker trials in the presence of measurement error.
-
Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema.
-
Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
-
Oral platelet glycoprotein IIb/IIIa inhibition.
-
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.
-
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
-
Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings.
-
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
-
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
-
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
-
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
-
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
-
Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
-
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group.
-
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
-
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
-
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.
-
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
-
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
-
Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
-
Prasugrel.
-
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
-
Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials.
-
Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer.
-
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
-
Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma.
-
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
-
Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
-
Primary tumor location as a prognostic factor in metastatic colorectal cancer.
-
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
-
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
-
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
-
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).
-
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
-
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
-
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
-
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
-
ROC curve estimation under test-result-dependent sampling.
-
Radiation Therapy Oncology Group. Research Plan 2002-2006. Tumor Utilization Committee.
-
Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
-
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia.
-
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
-
Recommendations for clinical trial evaluation of acute stroke therapies.
-
Reducing patient eligibility criteria in cancer clinical trials.
-
Reducing the costs of phase III cardiovascular clinical trials.
-
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.
-
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
-
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
-
Reporting of race and ethnicity in breast cancer research: room for improvement.
-
Response rate as an endpoint in clinical trials.
-
Results of radiation therapy in gastric cancer.
-
Routine use of zoledronic acid in early-stage breast cancer.
-
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
-
Safety of bevacizumab in patients with metastatic breast cancer.
-
Sample size and interim analysis issues for dose selection.
-
Sample size determination for comparing several survival curves with unequal allocations.
-
Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis.
-
Second-line chemotherapy for advanced hormone-refractory prostate cancer.
-
Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials.
-
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
-
Simulating Colorectal Cancer Trials Using Real-World Data.
-
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
-
Star-D: lessons learned and future implications.
-
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer.
-
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.
-
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
-
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
-
Surrogate markers of response to cancer immunotherapy.
-
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
-
Technosphere insulin: inhaled prandial insulin.
-
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.
-
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial.
-
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
-
The case against independent monitoring committees.
-
The design and evaluation of HIV-1 vaccines.
-
The disconnect between phase II and phase III trials of drugs for heart failure.
-
The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy.
-
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
-
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
-
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
-
The impact of sharing results of a randomized breast cancer clinical trial with study participants.
-
The importance of identifying and validating prognostic factors in oncology.
-
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
-
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
-
The role of amifostine as a radioprotector.
-
The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
-
The safety and efficacy of apixaban : where do we stand in 2013?
-
The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343.
-
Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.
-
Those in gene therapy should pay closer attention to lessons from hyperthermia.
-
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.
-
Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.
-
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.
-
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years.
-
Twenty-five year evolution of medical hormonal therapy for prostate cancer.
-
Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
-
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
-
Use of Direct Oral Anticoagulants in Special Populations.
-
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
-
Vinorelbine (Navelbine) in non-small cell lung cancer: future directions.
-
Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes.
-
Where does a Staphylococcus aureus vaccine stand?
-
Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
-
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
-
Keywords of People
-
Alexander, John Hunter Peel,
Professor of Medicine,
Medicine, Cardiology
-
Charles, Hal Cecil,
Adjunct Associate Professor in the Department of Radiology,
Radiology
-
O'Connor, Christopher Michael,
Adjunct Professor in the Department of Medicine,
Medicine, Clinical Pharmacology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Thomas, Melanie Byrne,
Associate Professor of Medicine,
Medicine, Medical Oncology